CTLA4 and hepatocellular carcinoma: Targeted blockade of CTLA-4 and PD-1/PD-L1 as forerunner molecular targets of cancer-related immune exhaustion has rapidly extended to HCC based on the promising results of ICPI therapy in multiple indications (Table 1, Fig. 3).